Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites.
Dysadherin, a cancer associated cell membrane glycoprotein, has been reported to downregulate E-cadherin. Aberrant expression of E-cadherin has been associated with the development of metastases in patients with cancer. Even though the expression of dysadherin and E-cadherin has been studied in primary non-small cell lung carcinoma, little is known about its expression at the distant metastases sites. We investigate by immunohistochemistry the relationship between E-cadherin and dysadherin in 111 cases of primary lung carcinomas (53 squamous cell carcinomas, 21 adenocarcinomas, 13 large cell carcinomas, and 24 small cell carcinomas), and their distant metastases. The intensity, the expression pattern and the percentage of neoplastic cell staining were recorded and the results were correlated with clinicopathological findings of the subjects. Dysadherin immunostain was expressed in 61 (54.95%) of the cases, and increased dysadherin expression was significantly correlated with tumour size (p=0.003), distant metastases (p=0.0034), and metastasis size (p=0.0008). Reduced E-cadherin expression was noted in 46 (41.45%) of the cases, and was correlated with high-grade tumour (p=0.02), infiltrative growth pattern (p=0.042), and advanced stage (p=0.032). Although the correlation between the expression of dysadherin and E-cadherin was not significant, a group of patients showed reduced E-cadherin expression with dysadherin overexpression. In lung carcinomas dysadherin expression seems to reflect tumour aggressiveness and may be considered a positive marker of poor prognosis when considered alone or/and in combination with down-regulation of E-cadherin.
Mitselou
Antigony
A
Department of Forensic Pathology, Ioannina University Medical School, Ioannina, Greece. amitselo@cc.uoi.gr
Batistatou
Anna
A
Nakanishi
Yukihiro
Y
Hirohashi
Setsuo
S
Vougiouklakis
Theodoros
T
Charalabopoulos
Konstantinos
K
D000230:Adenocarcinoma / Q000737:chemistry* / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD; D014408:Biomarkers, Tumor / Q000032:analysis*; D015820:Cadherins / Q000032:analysis*; D018287:Carcinoma, Large Cell / Q000737:chemistry* / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry* / Q000556:secondary; D018288:Carcinoma, Small Cell / Q000737:chemistry* / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000556:secondary; D016009:Chi-Square Distribution; D005260:Female; D006115:Greece; D006801:Humans; D007150:Immunohistochemistry; D007473:Ion Channels; D008175:Lung Neoplasms / Q000737:chemistry* / Q000473:pathology; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis*; D008840:Microfilament Proteins; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000032:analysis*; D009367:Neoplasm Staging; D011379:Prognosis
D015703:Antigens, CD; D014408:Biomarkers, Tumor; C513384:CDH1 protein, human; D015820:Cadherins; C451410:FXYD5 protein, human; D007473:Ion Channels; D008562:Membrane Glycoproteins; D008840:Microfilament Proteins; D009363:Neoplasm Proteins